search
Back to results

Innovative Interventions for Smoking Cessation

Primary Purpose

Tobacco Use Disorder

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Nicotine Patch
VLNC Cigarette
VLNC Cigarette Plus Nicotine Patch
Sponsored by
University of Minnesota
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tobacco Use Disorder focused on measuring Smoking Cessation, Nicotine Free Cigarettes

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • a) Smoking at least 10 cigarettes daily for the past year;
  • b) In good physical health;
  • c) No contraindications for medicinal nicotine; and
  • d) Stable, good mental health.

Exclusion Criteria:

  • a) Subjects must not be using other tobacco or nicotine products.
  • b) Female subjects cannot be pregnant or nursing and must be using appropriate birth control.

Sites / Locations

  • University of Minnesota
  • University of MN's Tobacco Use Research Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Experimental

Arm Label

VLNC Cigarette

Nicotine Patch

VLNC Cigarette plus Nicotine Patch

Arm Description

Very Low Nicotine Content Cigarette. Dosage: 0.05 mg to 0.09 mg nicotine yield cigarette; Frequency: Daily; Duration: 6 weeks.

21 mg nicotine patch. Dosage: 21 mg; Frequency: Daily; Duration: 6 weeks.

Very Low Nicotine Content Cigarette plus 21 mg Nicotine Patch. Patch Dosage: 21 mg; Cigarette Dosasge: 0.05 to 0.09 mg nicotine yield; Frequency: Daily; Duration: 6 weeks

Outcomes

Primary Outcome Measures

End of Treatment Abstinence Rate
Cotinine and carbon monoxide (CO) verified point prevalence abstinence
End of Follow-up Abstinence Rates
CO- and cotinine-verified point prevalence abstinence

Secondary Outcome Measures

Exposure to Tobacco Toxicants
Time to Lapse or Relapse to Tobacco Use

Full Information

First Posted
January 14, 2010
Last Updated
October 30, 2019
Sponsor
University of Minnesota
Collaborators
National Institute on Drug Abuse (NIDA)
search

1. Study Identification

Unique Protocol Identification Number
NCT01050569
Brief Title
Innovative Interventions for Smoking Cessation
Official Title
Innovative Interventions for Smoking Cessation: Comparison of Very Low Nicotine Content Cigarettes Plus Nicotine Patch; Very Low Nicotine Content Cigarettes Alone or Nicotine Patch Alone
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
October 2008 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
June 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Minnesota
Collaborators
National Institute on Drug Abuse (NIDA)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the effect of a combination of the 21 mg nicotine patch and very low nicotine content (VLNC) cigarettes compared to 21 mg nicotine patch only and very low nicotine content cigarette only on abstinence, time to relapse and toxicant levels. The study will determine if adding nicotine replacement medication to the very low content cigarettes (VLNC) will augment treatment compared to nicotine patch only or to very low nicotine content cigarettes only.
Detailed Description
The purpose of this study is to evaluate the effect of a combination of the 21 mg nicotine patch and very low nicotine content cigarette (VLNC) compared to the VLNC cigarette alone or 21 mg nicotine patch alone on abstinence, time to relapse and toxicant levels. The following primary hypothesis will be tested: Abstinence rates will be highest and the time to relapse will be the longest in the VLNC cigarettes plus nicotine patch condition compared to nicotine patch or VLNC cigarettes alone. Other hypotheses include: Greater positive subjective responses to cigarettes will be observed with VLNC cigarettes plus patch vs. VLNC cigarette; Less drop-outs will be observed in the VLNC plus patch vs the other two conditions; and Less compensatory smoking will be observed in the VLNC plus patch condition compared to VLNC cigarette alone condition. Cigarette smokers will be randomized to: VLNC cigarettes (which provide sensory behavioral aspects of smoking but with limited nicotine) plus nicotine patch for 6 weeks; Nicotine patch for 6 weeks; or VLNC cigarettes alone. Outcome measures will include cessation assessed at the end of treatment as the primary endpoint and at 36 weeks post-treatment, time to lapse and relapse to usual brand cigarettes, and biomarkers of toxicant exposure. Predictors of abstinence and treatment response for each of the treatment conditions will be explored.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tobacco Use Disorder
Keywords
Smoking Cessation, Nicotine Free Cigarettes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Factorial Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
235 (Actual)

8. Arms, Groups, and Interventions

Arm Title
VLNC Cigarette
Arm Type
Active Comparator
Arm Description
Very Low Nicotine Content Cigarette. Dosage: 0.05 mg to 0.09 mg nicotine yield cigarette; Frequency: Daily; Duration: 6 weeks.
Arm Title
Nicotine Patch
Arm Type
Active Comparator
Arm Description
21 mg nicotine patch. Dosage: 21 mg; Frequency: Daily; Duration: 6 weeks.
Arm Title
VLNC Cigarette plus Nicotine Patch
Arm Type
Experimental
Arm Description
Very Low Nicotine Content Cigarette plus 21 mg Nicotine Patch. Patch Dosage: 21 mg; Cigarette Dosasge: 0.05 to 0.09 mg nicotine yield; Frequency: Daily; Duration: 6 weeks
Intervention Type
Drug
Intervention Name(s)
Nicotine Patch
Other Intervention Name(s)
Nicoderm CQ
Intervention Description
21 mg
Intervention Type
Other
Intervention Name(s)
VLNC Cigarette
Other Intervention Name(s)
Quest 3, Xodus
Intervention Description
Cigarette where the tobacco contains <0.1 mg of nicotine yield.
Intervention Type
Other
Intervention Name(s)
VLNC Cigarette Plus Nicotine Patch
Other Intervention Name(s)
Nicoderm CQ, Quest 3, Xodus
Intervention Description
21 mg nicotine patch plus use of cigarette with tobacco containing <0.1 mg nicotine yield.
Primary Outcome Measure Information:
Title
End of Treatment Abstinence Rate
Description
Cotinine and carbon monoxide (CO) verified point prevalence abstinence
Time Frame
12 week
Title
End of Follow-up Abstinence Rates
Description
CO- and cotinine-verified point prevalence abstinence
Time Frame
36 weeks
Secondary Outcome Measure Information:
Title
Exposure to Tobacco Toxicants
Time Frame
6 weeks
Title
Time to Lapse or Relapse to Tobacco Use
Time Frame
26 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: a) Smoking at least 10 cigarettes daily for the past year; b) In good physical health; c) No contraindications for medicinal nicotine; and d) Stable, good mental health. Exclusion Criteria: a) Subjects must not be using other tobacco or nicotine products. b) Female subjects cannot be pregnant or nursing and must be using appropriate birth control.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dorothy Hatsukami, PhD
Organizational Affiliation
University of Minnesota
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Minnesota
City
Duluth
State/Province
Minnesota
ZIP/Postal Code
55812
Country
United States
Facility Name
University of MN's Tobacco Use Research Center
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55414
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
23603206
Citation
Hatsukami DK, Hertsgaard LA, Vogel RI, Jensen JA, Murphy SE, Hecht SS, Carmella SG, al'Absi M, Joseph AM, Allen SS. Reduced nicotine content cigarettes and nicotine patch. Cancer Epidemiol Biomarkers Prev. 2013 Jun;22(6):1015-24. doi: 10.1158/1055-9965.EPI-12-1439. Epub 2013 Apr 19.
Results Reference
result
PubMed Identifier
25192771
Citation
Dermody SS, Donny EC, Hertsgaard LA, Hatsukami DK. Greater reductions in nicotine exposure while smoking very low nicotine content cigarettes predict smoking cessation. Tob Control. 2015 Nov;24(6):536-9. doi: 10.1136/tobaccocontrol-2014-051797. Epub 2014 Sep 5.
Results Reference
derived

Learn more about this trial

Innovative Interventions for Smoking Cessation

We'll reach out to this number within 24 hrs